Similarly, Rossi et al. demonstrated strong anti-tumor activity of a CD20-targeted tetrameric IFNα in xenograft NHL models, and Yoo et al. showed delayed tumor growth with a CD138-targeted IFNα in a MM xenograft model [24, 47]. This evidence concerns the gene IFNA2 and non-Hodgkin lymphoma.